These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 11364399)

  • 41. FDA notifications. NRTI Emtriva receives FDA approval.
    AIDS Alert; 2003 Oct; 18(10):131-2. PubMed ID: 14686301
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A new approach for 'deep salvage' trials in advanced HIV infection.
    Lederman MM; Miller V; Weller I; Deeks SG
    AIDS; 2007 Jul; 21(12):1503-6. PubMed ID: 17630543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FDA notifications. New antiretroviral guidelines issued.
    AIDS Alert; 2005 Jan; 20(1):11-2. PubMed ID: 15717358
    [No Abstract]   [Full Text] [Related]  

  • 44. India research opportunities, price and patent problems: interview with David Scondras. Interview by John S. James.
    Scondras D
    AIDS Treat News; 1999 Jun; (No 321):1-5. PubMed ID: 11366715
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FDA notifications. Reyataz is approved for HIV treatment.
    AIDS Alert; 2003 Sep; 18(9):119-20. PubMed ID: 14686309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. On approval.
    Huff B
    GMHC Treat Issues; 2001 Oct; 15(10):5-8. PubMed ID: 11727570
    [No Abstract]   [Full Text] [Related]  

  • 48. FDA panel fails to recommend adefovir approval. Food and Drug Administration.
    Highleyman L
    BETA; 1999; 12(4):4. PubMed ID: 11367249
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.
    AIDS Alert; 2009 Sep; 24(9):106-7. PubMed ID: 19938313
    [No Abstract]   [Full Text] [Related]  

  • 50. Issues in the design of clinical trials for safety in HIV-infected children.
    Lindsey JC; Kline MW
    Pediatr AIDS HIV Infect; 1996 Apr; 7(2):69-82. PubMed ID: 11361484
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adaptive methods: telling "the rest of the story".
    Emerson SS; Fleming TR
    J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preventing mother-infant transmission worldwide: what is needed? Interview with Joseph Saba, M.D. Interview by John S. James.
    Saba J
    AIDS Treat News; 1998 May; (No 294):2-3, 6. PubMed ID: 11365403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical trial design issues in schizophrenic research.
    Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The science and marketing of simpler dosing.
    Proj Inf Perspect; 1997 Nov; (23):6-7. PubMed ID: 11365380
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How far can you knock down HIV? An interview with David D. Ho, MD. Interview by Mark Mascolini.
    Ho DD
    J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):40-4. PubMed ID: 11364429
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDA notifications. New guidance assists HIV drug development. Changes affect approvals for antiretroviral drugs.
    AIDS Alert; 2003 Jan; 18(1):10-1. PubMed ID: 12541998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 3TC receives full approval.
    Grodeck B; Vazquez E
    Posit Aware; 1997; 8(3):11. PubMed ID: 11364417
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Experimental drug quickly suppresses HIV.
    AIDS Read; 2005 Apr; 15(4):150. PubMed ID: 15844233
    [No Abstract]   [Full Text] [Related]  

  • 59. Long-term strategies: should some patients wait to start protease inhibitors? Interview with Keith Henry, M.D. Interview by John S. James.
    Henry K
    AIDS Treat News; 1997 Oct; (No 281):1, 3-6. PubMed ID: 11364791
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Weekend treatment interruptions for certain well-controlled patients: interview with Cal Cohen, M.D. Interview by John S. James.
    Cohen C
    AIDS Treat News; 2004; (407-408):2-4. PubMed ID: 15717379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.